TNF Pharmaceuticals, Inc.
TNFA
$0.22
$0.02814.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -38.54% | -22.47% | -11.90% | 56.06% | 36.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.07% | -25.43% | -11.44% | 33.33% | 7.05% |
| Operating Income | 47.07% | 25.43% | 11.44% | -33.33% | -7.05% |
| Income Before Tax | -483.98% | -339.60% | -34.82% | 2.37% | 73.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -483.98% | -339.60% | -34.82% | 2.37% | 73.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -483.98% | -339.60% | -34.82% | 2.37% | 73.68% |
| EBIT | 47.07% | 25.43% | 11.44% | -33.33% | -7.05% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -124.65% | -150.31% | -4.72% | 4.93% | 54.98% |
| Normalized Basic EPS | -289.62% | -162.66% | 23.74% | 35.94% | 77.42% |
| EPS Diluted | -75.60% | -96.65% | -19.38% | -10.30% | 42.41% |
| Normalized Diluted EPS | -114.90% | -73.01% | 1.50% | 13.45% | 59.06% |
| Average Basic Shares Outstanding | 57.37% | 51.61% | 43.28% | 30.56% | 19.16% |
| Average Diluted Shares Outstanding | -21.86% | -27.75% | 158.43% | 148.62% | 139.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.71% | -- | -- | -- | -- |